Semaglutide: A Promising Ally Against Alzheimer’s?
In a groundbreaking study, researchers at Case Western Reserve School of Medicine have identified a potential new benefit of semaglutide, a widely used diabetes and weight-loss drug. According to their findings, semaglutide may significantly reduce the risk of Alzheimer’s disease in individuals with type 2 diabetes (T2D), outperforming seven other anti-diabetic medications.
Alzheimer’s disease, a devastating brain disorder that erodes memory and cognitive abilities, affects nearly 7 million Americans aged 65 and older, as reported by the Alzheimer’s Association. Alarmingly, it claims more lives annually than breast and prostate cancer combined.
Published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study suggests that T2D patients taking semaglutide had a markedly lower risk of developing Alzheimer’s disease. This trend was consistent across various subgroups, regardless of obesity status, gender, or age.
Semaglutide, a glucagon-like peptide receptor (GLP-1R) agonist, is the active ingredient in popular medications like Wegovy and Ozempic. It works by reducing hunger and regulating blood sugar levels in T2D patients.
Under the leadership of Rong Xu, a professor of biomedical informatics, the research team analyzed three years of electronic health records from nearly one million U.S. patients with T2D. Their statistical approach, which mimicked a randomized clinical trial, revealed that patients prescribed semaglutide had a significantly lower risk of Alzheimer’s compared to those on other anti-diabetic medications.
According to the CDC, Alzheimer’s disease results in approximately 120,000 deaths annually, ranking as the seventh-leading cause of death in the United States.
“This new study provides real-world evidence for semaglutide’s potential impact on Alzheimer’s disease,” Xu stated. “While preclinical research has hinted at its protective effects against neurodegeneration and neuroinflammation, our findings suggest the need for further exploration through randomized clinical trials.”
Despite these promising results, the study’s limitations prevent researchers from drawing definitive causal conclusions. Xu emphasized the importance of continued research into semaglutide’s potential as a treatment for this debilitating condition, encouraging further investigation into alternative drugs.
For more information, please contact Patty Zamora at [email protected].
More Articles
Getting licensed or staying ahead in your career can be a journey—but it doesn’t have to be overwhelming. Grab your favorite coffee or tea, take a moment to relax, and browse through our articles. Whether you’re just starting out or renewing your expertise, we’ve got tips, insights, and advice to keep you moving forward. Here’s to your success—one sip and one step at a time!
Lofty has launched the industry’s first Agentic AI Operating System, a breakthrough platform that doesn’t just follow commands—it plans, executes, evaluates, and adapts entire workflows on its own. Designed specifically for real estate professionals, the system acts like an AI “orchestra,” coordinating specialized agents for lead qualification, marketing, SEO, transaction management, website creation, and more. With leaders calling this a major leap beyond traditional tools, Lofty AOS signals a new era where agents can focus on relationships and closings while AI handles the heavy lifting.
Florida’s insurance landscape is finally showing signs of stability as private insurers return and Citizens Property Insurance drops below 400,000 policies. Insurance Commissioner Michael Yaworsky says reforms are working, but homeowners may not feel relief yet as inflation and rebuilding costs keep premiums high. With transparency improvements, mitigation credits, and new AI regulations on the horizon, Florida aims to avoid another insurance crisis while keeping the market competitive and consumer‑friendly.
Mortgage rates just hit their lowest point since 2022, closing January at 6.18% and giving buyers and industry professionals a rare moment of relief. But while the Federal Reserve continues to pause rate hikes, economists warn that significant declines are unlikely. Most forecasts show rates hovering near 6% through 2026, with political uncertainty and inflation keeping markets volatile. For now, stability may be the best we get — and even that could be temporary.
Propy, a fast-growing real estate tech firm blending AI automation with blockchain-backed transaction systems, has secured a major $100 million credit facility to accelerate nationwide title company consolidation. The funding aims to modernize the traditionally slow, paper-heavy closing process, offering real estate professionals a faster, more secure, and more transparent experience. As automation reshapes the industry, staying educated on emerging technology will be essential for agents, brokers, mortgage professionals, and investors looking to stay competitive.
Escrow payments in Florida have jumped an astonishing 70% since 2019, far outpacing the national average and now consuming nearly 38% of a typical monthly mortgage payment. Surging insurance premiums and rising property taxes are driving the increase, reshaping affordability for homeowners and pricing out many would‑be buyers.
After losing their Altadena home in the LA wildfires, Jessica and Matt Conkle expected State Farm to help them rebuild. Instead, they faced months of delays, low valuations, and stalled claims — a struggle shared by nearly 80 percent of wildfire survivors. As insurers pull out of high‑risk areas and premiums soar, the crisis is reshaping homeownership, tightening mortgage approvals, and straining government safety nets. What’s happening in California is rapidly becoming a national issue, with real estate, mortgage, and insurance professionals on the front lines of a system under unprecedented pressure.
